|
Dysostoses
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
FGFR2 encodes a fibroblast growth factor receptor whose mutations are responsible for the Crouzon syndrome, involving craniosynostosis and facial dysostosis with shallow orbits.
|
29848297 |
2018 |
|
Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Bleomycin-enhanced alternative splicing of fibroblast growth factor receptor 2 induces epithelial to mesenchymal transition in lung fibrosis.
|
30049844 |
2018 |
|
Renal fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using Sprague-Dawley rats and rat renal proximal tubular cells (NRK52E), we determined the potential involvement of Fgf10, Fgfr2 and AR in DBP-induced renal fibrosis.
|
28919491 |
2018 |
|
Idiopathic pulmonary hypertension
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Intriguingly, the expression levels of FGF7, FGF10, and FGFR2 were lower in IPF lung regions undergoing active remodeling, and inversely correlated with IPAH severity, indicating that increased expression might reflect lung repair rather than lung pathology, and warranting further research on the precise role of FGF signaling in pulmonary parenchymal and vascular remodeling.
|
29722558 |
2018 |
|
Carcinoma, Lewis Lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigate gene dosage effects of Vegfr2, Fgfr1, and Fgfr2 in three independent mouse models of tumorigenesis: two-stage skin chemical carcinogenesis, and sub-cutaneous transplantation of B16F0 melanoma and Lewis Lung Carcinoma (LLC).
|
30283071 |
2018 |
|
Irido-corneal dysgenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Despite long axial lengths, shallow anterior chambers with occluded angles are possible in Crouzon syndrome and are most likely caused by FGFR2-related anterior segment dysgenesis.
|
29557836 |
2018 |
|
Metastatic Renal Cell Cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This analysis found a relationship between the expression of IL-8 and FGFR2 in mRCC patients treated with targeted agents.
|
29715147 |
2018 |
|
Non-Functioning Pituitary Gland Neoplasm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The association of the fibroblast growth factor receptor 2 gene (<i>FGFR2</i>) polymorphism rs2981582 with breast cancer has been extensively studied, whereas the role of this polymorphism in non-functioning pituitary adenoma (NFPA) has not been elucidated.
|
30206133 |
2018 |
|
Malignant neoplasm of gastrointestinal tract
|
0.010 |
Biomarker
|
disease |
BEFREE |
Generation of high-affinity, internalizing anti-FGFR2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers.
|
29420662 |
2018 |
|
Autism Spectrum Disorders
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data indicate that NEGR1 and FGFR2 cooperatively regulate cortical development and suggest a role for defective NEGR1-FGFR2 complex and convergent downstream ERK and AKT signalling in autism spectrum disorders.
|
30059965 |
2018 |
|
Metastatic Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This analysis found a relationship between the expression of IL-8 and FGFR2 in mRCC patients treated with targeted agents.
|
29715147 |
2018 |
|
Barrett Esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overexpression of cell surface fibroblast growth factor receptor 2 (FGFR2) is an early event in progression of BE to EAC, and is a promising imaging target.
|
29152066 |
2017 |
|
Giant Cell Tumors
|
0.010 |
AlteredExpression
|
group |
BEFREE |
This sensitivity was consistent with the target expression patterns of giant cell tumor PDCs (FGFR2-IIIC mRNA expression in giant cell tumor PDCs originated from the right pulmonary nodule was increased significantly as compared to those originated from left).
|
28445128 |
2017 |
|
Pituitary Adenoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to determine the association between sirtuin 1 (<i>SIRT1</i>), fibroblast growth factor receptor 2 (<i>FGFR2</i>) and signal transducer and activator of transcription 3 (<i>STAT3</i>) polymorphisms, and pituitary adenoma (PA) development, invasiveness, hormonal activity and recurrence.
|
28521414 |
2017 |
|
Vitiligo
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, within the transcriptional framework of VL, we identify five novel molecules (STAT1, PRKCD, PTPN6, MYC and FGFR2) that lend themselves to being targeted by drugs for future potential VL-therapy.
|
28129744 |
2017 |
|
Linear atrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aberrant splicing of Fgfr2 blocked stria vascularis formation due to erroneous ligand usage, which was corrected by reducing Fgf9 gene dosage.
|
29107558 |
2017 |
|
Malignant tumor of small intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
Application of this assay on prospective patient samples uncovered OLFM4 as a novel RET fusion partner in a small-bowel cancer and led to the discovery of a KLK2-FGFR2 fusion in a patient with prostate cancer who subsequently underwent treatment with a pan-fibroblast growth factor receptor inhibitor.
|
28802831 |
2017 |
|
Adrenocortical carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In 18 evaluable patients with FGFR genetic alterations, 3 confirmed partial responses (two intrahepatic cholangiocarcinomas (iCCA) with FGFR2 fusions and one urothelial cancer with FGFR2 and FGF19 amplification) and two durable stable disease at ⩾16 weeks with tumour reduction (FGFR2 fusion-positive iCCA and adrenocortical carcinoma with FGFR1 amplification) were observed.
|
28972963 |
2017 |
|
Malignant ascites
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two GC patients with FGFR2 amplification confirmed by fluorescence in situ hybridization showed peritoneal seeding and malignant ascites.
|
28501555 |
2017 |
|
Small intestine carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Application of this assay on prospective patient samples uncovered OLFM4 as a novel RET fusion partner in a small-bowel cancer and led to the discovery of a KLK2-FGFR2 fusion in a patient with prostate cancer who subsequently underwent treatment with a pan-fibroblast growth factor receptor inhibitor.
|
28802831 |
2017 |
|
Carcinomatosis of peritoneal cavity
|
0.010 |
Biomarker
|
disease |
BEFREE |
We evaluated the antitumor activity of an FGFR inhibitor in FGFR2-amplified GC patients with peritoneal carcinomatosis.
|
28501555 |
2017 |
|
Invasive Ductal Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Analysis of tissue samples from patients with invasive ductal carcinoma revealed an inversed correlation between expression of FGFR2 and ER, thus supporting our in vitro data.
|
28869838 |
2017 |
|
Papillary Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
|
27379982 |
2017 |
|
VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, within the transcriptional framework of VL, we identify five novel molecules (STAT1, PRKCD, PTPN6, MYC and FGFR2) that lend themselves to being targeted by drugs for future potential VL-therapy.
|
28129744 |
2017 |
|
Refractory Cytopenia of Childhood
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Up to date, there are no data about FGFR2 expression and its predictive role in papillary RCC (pRCC) patients.
|
27379982 |
2017 |